Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Abstract:
The article offers information on the failure of the phase III STARSCAPE trial, which studied recombinant human pentraxin-2, zinpentraxin alfa, in 664 patients with idiopathic pulmonary fibrosis (IPF). Topics include the trial's early termination due to futility, lack of benefit of zinpentraxin alfa compared to placebo on lung function and other outcomes, and the challenges in translating successful phase II trials to phase III trials in IPF.
No Comments.